Monday, 2 November 09:00 – 12:00

SC1: Engineering of Bispecific Antibodies

Co-instructors:
Nicolas Fischer, Ph.D., Head, Research, Novimmune SA

Michela Silacci, Director, Discovery Research, Covagen AG, one of the Janssen Pharmaceutical Companies of J&J

By attending this interactive workshop, you will learn about the various approaches used for the engineering of bispecific antibodies and bispecific scaffold-based binding proteins. Different technologies will be compared, and examples for applications of bispecific antibodies in drug development will be presented with a focus on candidates that are currently being evaluated in clinical trials. Opportunities and challenges in the field of bispecific antibodies will be discussed.

• Overview on bispecific antibody technologies
• Past and current challenges for bispecific antibody development
• Alternative scaffold-based bispecifics
• Case studies of bispecific antibodies in clinical development
• Discussion of applications and opportunities for bispecific antibodies